摘要
目的 了解亳州市人民医院使用依达拉奉右莰醇注射用浓溶液的情况,为规范临床合理应用提供依据。方法 回顾性随机抽取2022年9月—2023年2月在亳州市人民医院使用依达拉奉右莰醇注射用浓溶液150份患者病历,从适应证、用法用量、使用疗程、禁忌证等方面进行合理性评价。结果 150份病历中,用药不合理病历共计70份(46.67%),其中超适应证用药30份(20.00%)、超医保支付限制适应证用药33例(22.00%)、给药剂量不适宜31份(20.67%)、给药频次不适宜4份(2.67%)、超疗程用药3份(2.00%)、用药时机不适宜3份(2.00%)、溶媒剂量不适宜9份(6.00%)和超禁忌症用药1份(0.67%)。结论 依达拉奉右莰醇注射用浓溶液在临床使用存在超适应证用药、剂量不适宜、超疗程用药等不合理问题,应引起临床药师和医生高度重视,促进合理用药。
Objective To investigate the use of Edaravone and Dexborneol Concentrated Solution for injection in Bozhou People's Hospital,and to provide basis for clinical rational application.Methods The medical records of 150 patients who used Edaravone and Dexborneol Concentrated Solution for injection in the Bozhou People's Hospital from September 2022 to February 2023 were randomly selected retrospectively,and the rationality was evaluated from the indications,dosage,course of treatment,contraindications.Results Among the 150 medical records,70 cases(46.67%)were unreasonable.Among them,there were 30 cases(20.00%)of off-label drug use,33 cases(22.00%)of drugs used for indications beyond the payment limit of medical insurance,31 cases(20.67%)of inappropriate dose,4 cases(2.67%)of inappropriate frequency of drug administration,3 cases(2.00%)of excessive drug use,3(2.00%)cases of inappropriate timing of drug use,9 cases(6.00%)of inappropriate solvent dose,and 1 case(0.67%)was super-contraindications.Conclusion There are unreasonable problems in the clinical use of Edaravone and Dexborneol Concentrated Solution for injection,such as over-indication,inappropriate dose,over-treatment and so on.Clinical pharmacists and doctors should pay high attention to it and promote rational use of drugs.
作者
张清
赵欢欢
赵凯博
丁臻
ZHANG Qing;ZHAO Huan-huan;ZHAO Kai-bo;DING Zhen(Department of Pharmacy,Bozhou People's Hospital,Bozhou 236800,China;Department of Pharmacy,Anhui Provincal Children's Hospital,Hefei 230022,China)
出处
《现代药物与临床》
CAS
2023年第7期1762-1766,共5页
Drugs & Clinic
关键词
依达拉奉右莰醇
急性脑梗死
合理用药
超医保支付
适应证
Edaravone and Dexborneol Concentrated Solution for injection
acute cerebral infarction
rational drug use
indications beyond the payment limit of medical insurance
indication